Article Versions Notes

Krafft U, Olah C, Reis H, Kesch C, Darr C, Grünwald V, Tschirdewahn S, Hadaschik B, Horvath O, Kenessey I, et al. High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. Cancers. 2021; 13(11):2548. https://doi.org/10.3390/cancers13112548

Krafft, Ulrich, Csilla Olah, Henning Reis, Claudia Kesch, Christopher Darr, Viktor Grünwald, Stephan Tschirdewahn, Boris Hadaschik, Orsolya Horvath, Istvan Kenessey, and et al. 2021. "High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy" Cancers 13, no. 11: 2548. https://doi.org/10.3390/cancers13112548

Krafft, U., Olah, C., Reis, H., Kesch, C., Darr, C., Grünwald, V., Tschirdewahn, S., Hadaschik, B., Horvath, O., Kenessey, I., Nyirady, P., Varadi, M., Modos, O., Csizmarik, A., & Szarvas, T. (2021). High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. Cancers, 13(11), 2548. https://doi.org/10.3390/cancers13112548